Vivatides Therapeutics
Develops extrahepatic RNA-targeting therapeutics
$54MSeries A
Role not disclosedTC
TF Capital
Activity from announced rounds
Activity in this selectiona16z-bio-health-1883279d
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.5B 2 disclosed · full round size, not this investor’s share